The last decade has witnessed the evolution of treatment for advanced RCC, as the application of receptor tyrosine kinase (RTK) inhibitor drugs such as sunitinib and pazopanib greatly improves the disease-free survival of advanced RCC patients. This evidence concerns the gene NTRK1 and renal cell carcinoma.